Complement Activation, Its Consequences, and Blockade by Gene Transfer

[1]  D. White,et al.  Novel responses by transgenic pig endothelial cells to stimulation by human cytokines in terms of H-DAF, E-selectin and major histocompatibility complex class II expression. , 1997, Transplantation proceedings.

[2]  J. Platt,et al.  Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. , 1997, Transplantation.

[3]  A. Dalmasso,et al.  Expression of human CD59 in transgenic pig organs enhances organ survival in an ex vivo xenogeneic perfusion model. , 1996, Transplantation.

[4]  C. Hammer,et al.  Cross Species Interaction of xenogeneic interleukins. , 1996, Transplantation proceedings.

[5]  T. Seya,et al.  C5b‐8 Step Lysis of Swine Endothelial Cells by Human Complement and Functional Feature of Transfected CD59 , 1996, Scandinavian journal of immunology.

[6]  A. Tucker,et al.  A line of transgenic pigs in which the expression of human decay‐accelerating factor by endothelial cells is increased in the presence of inflammatory stimuli , 1996 .

[7]  E. Cozzi,et al.  Production of pigs transgenic for human DAF: A strategy for xenotransplantation , 1995 .

[8]  B. Morgan.  Complement regulatory molecules: application to therapy and transplantation. , 1995, Immunology today.

[9]  N. Cary,et al.  TISSUE EXPRESSION OF HUMAN COMPLEMENT INHIBITOR, DECAY‐ACCELERATING FACTOR, IN TRANSGENIC PIGS A POTENTIAL APPROACH FOR PREVENTING XENOGRAFT REJECTION , 1995, Transplantation.

[10]  J. Platt,et al.  Identification of porcine endothelial cell membrane antigens recognized by human xenoreactive natural antibodies. , 1995, Journal of immunology.

[11]  J. Platt,et al.  TRANSGENIC EXPRESSION OF HUMAN COMPLEMENT REGULATORY PROTEINS IN MICE RESULTS IN DIMINISHED COMPLEMENT DEPOSITION DURING ORGAN XENOPERFUSION , 1995, Transplantation.

[12]  E. Cozzi,et al.  Production of pigs transgenic for human regulators of complement activation. , 1995, Transplantation proceedings.

[13]  E. Cozzi,et al.  Expression of human DAF and MCP on pig endothelial cells protects from human complement. , 1995, Transplantation proceedings.

[14]  A. Dalmasso,et al.  Activation of intragraft endothelial and mononuclear cells during discordant xenograft rejection. , 1994, Transplantation.

[15]  M. Sandrin,et al.  Galα(1,3)Gal, the Major Xenoantigen(s) Recognised in Pigs by Human Natural Antibodies , 1994, Immunological reviews.

[16]  F. Bach,et al.  Depletion of IgM Xenoreactive Natural Antibodies by Injection of anti‐μ Monoclonal Antibodies , 1994, Immunological reviews.

[17]  H. Izutani,et al.  EFFECTS OF TRANSFECTED COMPLEMENT REGULATORY PROTEINS, MCP, DAF, AND MCP/DAF HYBRID, ON COMPLEMENT‐MEDIATED SWINE ENDOTHELIAL CELL LYSIS , 1994, Transplantation.

[18]  J. Platt,et al.  Porcine endothelial cell antigens recognized by human natural antibodies. , 1994, Transplantation proceedings.

[19]  B. Morgan,et al.  Complement-inhibiting activities of human CD59 and analogues from rat, sheep, and pig are not homologously restricted. , 1994, Journal of immunology.

[20]  F. Bach,et al.  In vivo IgM depletion by anti-mu monoclonal antibody therapy. The role of IgM in hyperacute vascular rejection of discordant xenografts. , 1994, Transplantation.

[21]  A. Kirk,et al.  The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. , 1994, Transplantation.

[22]  M. Sandrin,et al.  Anti-pig IgM antibodies in human serum react predominantly with Gal(alpha 1-3)Gal epitopes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. Oriol,et al.  CARBOHYDRATE ANTIGENS OF PIG TISSUES REACTING WITH HUMAN NATURAL ANTIBODIES AS POTENTIAL TARGETS FOR HYPERACUTE VASCULAR REJECTION IN PIG‐TO‐MAN ORGAN XENOTRANSPLANTATION1 , 1993, Transplantation.

[24]  W. Baldwin,et al.  THE EFFECT OF XENOREACTIVE ANTIBODY AND B CELL DEPLETION ON HYPERACUTE REJECTION OF GUINEA PIG‐TO‐RAT CARDIAC XENOGRAFTS1 , 1993, Transplantation.

[25]  U. Galili.  Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: a major obstacle for xenotransplantation in humans. , 1993, Immunology today.

[26]  N. Cary,et al.  Tissue expression of human decay accelerating factor, a regulator of complement activation expressed in mice: a potential approach to inhibition of hyperacute xenograft rejection. , 1993, Transplantation proceedings.

[27]  D. Purcell,et al.  Tissue‐specific and allelic expression of the complement regulator CD46 is controlled by alternative splicing , 1992, European journal of immunology.

[28]  N. Cary,et al.  Hyperacute rejection of rabbit hearts by human blood is mediated by the alternative pathway of complement. , 1992, Transplantation proceedings.

[29]  S. Gore,et al.  Organ donation from intensive care units in England and Wales: two year confidential audit of deaths in intensive care. , 1992, BMJ.

[30]  P. Taillon-Miller,et al.  Analysis of the human regulators of complement activation (RCA) gene cluster with yeast artificial chromosomes (YACs). , 1992, Genomics.

[31]  D. Hourcade,et al.  Expression of human decay accelerating factor or membrane cofactor protein genes on mouse cells inhibits lysis by human complement , 1992, Transplant international : official journal of the European Society for Organ Transplantation.

[32]  A. Dalmasso,et al.  REACTION OF COMPLEMENT WITH ENDOTHEUAL CELLS IN A MODEL OF XEN0TRANSPLANTATION , 1991, Clinical and experimental immunology.

[33]  J. Atkinson,et al.  SEPARATION OF SELF FROM NON‐SELF IN THE COMPLEMENT SYSTEM: A ROLE FOR MEMBRANE COFACTOR PROTEIN AND DECAY ACCELERATING FACTOR , 1991, Clinical and experimental immunology.

[34]  T. Kinoshita.  Biology of complement: the overture. , 1991, Immunology today.

[35]  J. Platt,et al.  Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Potential for prevention of xenograft hyperacute rejection. , 1991, Transplantation.

[36]  J. Platt,et al.  Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. , 1991, Transplantation.

[37]  J. Platt,et al.  Neutrophil adhesion to xenogeneic endothelium via iC3b. , 1991, Journal of immunology.

[38]  J. Platt,et al.  Endothelial cell antigens recognized by xenoreactive human natural antibodies. , 1990, Transplantation.

[39]  J. Atkinson,et al.  Structure of the gene for human complement protein decay accelerating factor. , 1990, Journal of immunology.

[40]  R. Palmiter,et al.  Introns increase transcriptional efficiency in transgenic mice. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[41]  U. Galili,et al.  A Unique Natural Human Igg Antibody with Anti-a-galactosyl Specificity , 2022 .

[42]  D. Fearon,et al.  Increased expression of C3b receptors on polymorphonuclear leukocytes induced by chemotactic factors and by purification procedures. , 1983, Journal of immunology.

[43]  P. Concannon,et al.  Pregnancy and parturition in the bitch. , 1977, Biology of reproduction.

[44]  K. Reemtsma.  Heterotransplantation: theoretical considerations. , 1971, Transplantation proceedings.

[45]  K. Reemtsma,et al.  RENAL HETEROTRANSPLANTATION FROM NONHUMAN PRIMATES TO MAN , 1969, Annals of the New York Academy of Sciences.

[46]  D. White,et al.  Alteration of complement activity: a strategy for xenotransplantation. , 1996, Trends in biotechnology.

[47]  J. Wallwork,et al.  Genetic engineering of the donor species to control hyperacute xenograft rejection. , 1995, Advances in nephrology from the Necker Hospital.

[48]  J. Wallwork,et al.  The control of hyperacute rejection by genetic engineering of the donor species , 1995, Eye.

[49]  J. Atkinson,et al.  Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. , 1991, Annual review of immunology.

[50]  R. Calne.  Organ transplantation between widely disparate species. , 1970, Transplantation proceedings.